# Candesartan

## Blopress 8mg

#### 一般可用

| 藥品代碼       | OBLO                                                                                                                                                                                                                                      |
|:---------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症         | Heart failure， (NYHA class II to IV， ejection fraction 40% or less) to reduce cardiovascular mortality and hospitalizations. Hypertension.                                                                                              |
| 用法用量       | The recommended initial dose and maintenance dose is 8 mg， which could be increased to 16 mg. If poor control after four weeks with 16 mg once a day， the maximum dose can be increased to 32 mg once a day.                            |
| 肝功能異常     | 需調整劑量                                                                                                                                                                                                                                |
| 腎功能異常     | 需調整劑量                                                                                                                                                                                                                                |
| 禁忌           | Concomitant use with aliskiren in diabetic patients. Hypersensitivity to candesartan. Severe hepatic impairment &/or cholestasis. Lactating women and women in the second and third trimesters of pregnancy. Children under one year old. |
| 副作用         | Common Cardiovascular: Hypotension (18.8% ) Musculoskeletal: Backache (3% .) Neurologic: Dizziness (less than 5% ) Respiratory: Pharyngitis (2% )， Rhinitis (2% )， Upper respiratory infection (6% )                                    |
| 孕期用藥建議   | Human data suggest risk in 2nd and 3 rd trimesters                                                                                                                                                                                        |
| 哺乳期用藥建議 | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                       |

